Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of a novel anti-PD-L1/TGF-β bifunctional fusion protein in recurrent cervical cancer.

Hum Vaccin Immunother · 2026 · PMC13011592 · PMID 41866914

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In the future, more clinical studies are needed to explore the objective response rates (ORR) and progression-free survival (PFS) in cervical cancer patients treated with TGF-β/PD-L1 inhibitors. In the full-course treatment in our study, the absolute value of peripheral blood lymphocytes in patients with PR showed an increasing trend, while that in patients with PD showed the opposite trend.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.